Last edition
News about "Shreehas Tambe"
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili
Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.
Shreehas Tambe | 09/07/2026 | By News Bureau | 106
Biocon Expands Diabetes Care in Malaysia as Duopharma Wins Insulin Tenders
Biocon strengthens diabetes care in Malaysia as Duopharma Biotech secures insulin tenders worth over MYR 225 million for human insulin, insulin glargine, and insulin aspart.
Shreehas Tambe | 26/06/2026 | By News Bureau
Biocon Launches Bosaya and Aukelso Denosumab Biosimilars in US
Biocon launches Bosaya and Aukelso denosumab biosimilars in the US following FDA approval with interchangeable status, expanding treatment options for osteoporosis and bone metastasis patients.
Shreehas Tambe | 08/04/2026 | By News Bureau | 119
Biocon Biologics Secures Global Rights to Hulio
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.
Shreehas Tambe | 23/12/2025 | By News Bureau | 226
Biocon Biologics and Civica Launch Private-Label Insulin Glargine in the US
The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialise under Biocon Biologics’ existing marketing approval.
Shreehas Tambe | 21/10/2025 | By Dineshwori | 261
Biocon Biologics Secures FDA Approval for Kirsty
Biocon Biologics has announced that it has received FDA approval for KIRSTY (Insulin Aspart-xjhz), making it the first and only interchangeable biosimilar to NovoLog in the US, marking a major milestone in expanding affordable insulin options.
Shreehas Tambe | 16/07/2025 | By Mrinmoy Dey | 319
Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health
Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.
Shreehas Tambe | 03/07/2025 | By Mrinmoy Dey | 241
Biocon Biologics appoints Shreehas Tambe as MD and CEO
Tambe has shaped and grown the company's biosimilars business
Shreehas Tambe | 06/12/2022 | By Sudeep Soparkar | 825
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy